AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02600858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper limb feeding training
Description: Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days.
Study NCT02600858 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Upper limb feeding training
Description: Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days.
Study NCT03153852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Jessner's solution
Description: Modified Jessner's solution will be applied on the right side until frosting
Study NCT04594551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified vero rabies vaccine - serum free
Description: Pharmaceutical form:freeze-dried - Route of administration: intramuscular
Study NCT04594551 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine
Description: Pharmaceutical form:freeze-dried - Route of administration: intramuscular
Study NCT04594551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rabies immunoglobulins
Description: Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
Study NCT04594551 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human rabies immunoglobulins
Description: Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
Study NCT04232748 — intervention group
Intervention type: DRUG
Intervention: first line systemic treatment for colorectal cancer
Description: systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
Study NCT03153852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Description: Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
Study NCT03153852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid
Description: Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
Study NCT06656858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching
Description: Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds
Study NCT06656858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF stretching
Description: PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
Study NCT06656858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching with BFR
Description: Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
Study NCT06656858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching with BFR
Description: PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
Study NCT06656858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
Study NCT05181566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement arthroplasty using conventional acetabular cup
Description: In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
Study NCT02301975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
Description: FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
Study NCT02301975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation powders via ELLIPTA inhaler
Description: Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
Study NCT02301975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler
Description: FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
Study NCT02301975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
Description: Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
Study NCT02301975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Description: FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
Study NCT03173547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 146-9251 cream
Description: 146-9251 cream contains an active drug and is applied topically.
Study NCT03173547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream does not contain an active drug and is applied topically.
Study NCT02834663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-00241939 300 ug using inhaler A
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: PF-00241939 300 ug using inhaler A
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: PF-00241939 300 ug using inhaler A
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment D
Description: PF-00241939 300 ug using inhaler B
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment E
Description: PF-00241939 300 ug using inhaler B
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment F
Description: PF-00241939 300 ug using inhaler B
Study NCT01181700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment G
Description: PF-00241939 300 ug using inhaler B
Study NCT02728674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Person in the case is a male.
Description: Person in the case is a male.
Study NCT02728674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Person in the case is a female.
Description: Person in the case is a female.
Study NCT02728674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Symptom in the case is breathlessness.
Description: Symptom in the case is breathlessness.
Study NCT03614247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery
Description: The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
Study NCT03614247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-PNL
Description: The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
Study NCT03614247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-mini PNL
Description: The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
Study NCT03614247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-PNL
Description: The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
Study NCT03614247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PNL
Description: The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
Study NCT04083495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATLCAR.CD30 T cells
Description: Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells
Study NCT04083495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
Study NCT04083495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
Study NCT04083495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
Study NCT02842931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21
Description: R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
Study NCT02842931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21 + auto-SCT
Description: R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
Study NCT02842931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mNHL-BFM-90
Description: R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Study NCT02842931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mNHL-BFM-90 + auto-SCT
Description: R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Study NCT00000264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30% Nitrous oxide
Study NCT00000264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide
Study NCT00000264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.35 g/Kg ethanol
Study NCT00000264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.7 g/Kg ethanol
Study NCT00000264 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0 g/Kg ethanol
Study NCT02714530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tarceva daily during radiotherapy course
Study NCT02714530 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy
Study NCT02714530 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy
Study NCT03050125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar drop 1
Description: 180 mOsmol sterile saline drops used as a contact lens rewetting drop.
Study NCT00691379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
Study NCT00691379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
Study NCT00691379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
Study NCT00350285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Personal feedback with counselor using motivational interviewing strategies.
Study NCT00350285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Marijuana education
Description: Information about health and behavioral effects of marijuana use.
Study NCT03060681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block
Description: After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
Study NCT02924961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon PS total knee system with mobile-bearing
Study NCT02924961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PS total knee system with fixed-bearing
Study NCT03942588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Study NCT03841292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
Study NCT03050125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar drop 2
Description: 240 mOsmol sterile saline drops used as a contact lens rewetting drop.
Study NCT03841292 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Varenicline
Description: Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
Study NCT03841292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
Study NCT03841292 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
Study NCT00226655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCRF [XERECEPT (corticorelin acetate injection)]
Description: 2mg/day
Study NCT00691964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
Study NCT00691964 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: SQ injection 50 mg BIW
Study NCT00691964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SQ placebo injections for ABT-874 and etanercept
Study NCT03329001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Tablet
Description: Niraparib tablet formulation
Study NCT03329001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Capsule
Description: Niraparib capsule formulation
Study NCT00622518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyland's earache drops
Description: 3-4 drops in affected ear 3 times a day as needed for up to 5 days
Study NCT04167670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Over-encapsulated tablets administered orally.
Study NCT04167670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Capsules administered orally.
Study NCT04167670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Capsules administered orally.
Study NCT04167670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Tablets administered orally.
Study NCT04167670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Tablets administered orally.
Study NCT04167670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Over-encapsulated capsules administered orally.
Study NCT04952896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Synovitis diagnosis
Study NCT04655872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TPN171H
Description: A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
Study NCT02262871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen cannula
Description: HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
Study NCT02262871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
Study NCT04022694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to beverage health information
Description: Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information